Shenhua Shi

Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities

Hao Shao, Shenhua Shi, Shi‐Liang Huang et al. · Journal of Medicinal Chemistry · 2013 · 121 citations · Full text

Structure–activity Relationship, Drug Target, Heterocycle Chemistry +17

Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity

Alison J. Hole, Sonja Baumli, Hao Shao et al. · Journal of Medicinal Chemistry · 2012 · 68 citations · Full text

Functional Studies, Drug Target, Molecular Biology +24

CDKI‐71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol

Xiangrui Liu, Shenhua Shi, Frankie Lam et al. · International Journal of Cancer · 2011 · 60 citations · Full text

Chemoprevention Strategy, Immunology, Cell Death +18

Synthesis, structure–activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents

Hao Shao, Shenhua Shi, David Foley et al. · European Journal of Medicinal Chemistry · 2013 · 58 citations · Full text

Structure–activity Relationship, Potential Anti-tumour Agents, Medicine +7

In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83

Xiangrui Liu, Frankie Lam, Shenhua Shi et al. · Investigational New Drugs · 2011 · 14 citations

Cancer Research, Medicine, Receptor Tyrosine Kinase +8